@johndprent, the company announced the completion of the dose escalation phase for Avent AML trial in December of last year.
https://announcements.asx.com.au/asxpdf/20241216/pdf/06cpcddmq5bw9z.pdf
So we are up to the dose expansion cohort now which is enrolling older / unfit patients with newly diagnosed adverse / intermediate risk in AML or ineligible for chemo:
https://www.clinicaltrials.gov/study/NCT05834244?term=NCT05834244&rank=1As I mentioned in a previous post, Dr Maiti mainly focuses on adverse risk patients in his Zoom presentation. MD Anderson will complete a retrospective randomised trial using other data they have on file for each sub population to determine whether there is clinical benefit for this new triplet therapy. Dr Maiti gave a range in efficacy for standard of care therapy in respect complete responses between 40-60%. The key metric though is the 1 year survival rate which he is hoping to increase from ~40% by another 15-20%.
A few more call outs:
- as at the 31 Mar Qtrly, only 1 patient had been dosed and a second enrolled. This means that at least 2 of the patients and potentially all 3 patients have not completed all their 4 cycles of NK therapy (because this would take at least 4 months per patient).
@Shellbell mentioned in an earlier post that they only received one cycle of NK each! Hoping she can confirm if this been validated by the company;
- The CRi responses can potentially transition to CR responses over time because neutrophil and/or platelet counts gradually recover after the bone marrow achieves remission. CR responses are correlated with improved patient outcomes;
- At this stage, we only have immature data for a very small sample with limited details in respect to the patient characteristics.
Here is the trial protocol for your reference:
(20min delay)